摘要
目的观察克拉霉素联合噻托溴胺治疗慢性阻塞性肺疾病(COPD)患者的临床疗效和肺功能变化。方法选取符合入选条件的COPD患者120例,其中肺炎衣原体(Cpn)感染阳性患者78例。随机分成T组(用噻托溴胺治疗)和CT组(用克拉霉素+噻托溴胺治疗),每组60例。分别检测其抗Cpn抗体、C反应蛋白(CRP)、肺功能并评价其临床症状的改善情况。结果治疗后两组患者临床症状均明显好转,CT组好转程度较T组更明显(P<0.05);两组肺通气功能均有明显好转,1秒用力呼气容积/用力肺活量(FEV1/FVC)%及FEV1%,CT组增加程度较T组更明显(P<0.05);两组的CRP含量均下降,但CT组(P=0.000 0)比T组(P=0.0264)更显著;治疗前后Cpn-IgA、IgG阳性率比较,两组变化均不明显(P>0.05),Cpn-IgM阳性率比较仅CT组有显著变化(P<0.05)。结论克拉霉素联合噻托溴胺治疗COPD可起协同作用,使疗效更佳,因此CT方案值得临床推荐。
Objective To observe the clinical efficacy and the changes of pulmonary function of clarithromycin combined with tiotropium bromide for treating chronic obstructive pulmonary disease（COPD）. Methods 120 patients with COPD, including 78 cases of Chlamy-dophila pneumoniae（Cpn） positive infection, were selected and randomly divided into the group T treated with tiotropium bromide and the group CT treated with clarithromycin and tiotropium bromide, 60 cases in each group. The anti- Cpn antibodies, CRP and lung function were determined and the improvement of clinical symptoms were evaluated in the two groups. Results The clinical symptoms ＇after treatment in the two groups were significantly improved, but the improvement degree in the group CT was more significant than that in the group T （P 〈 0. 05）. The pulmonary ventilation function in the two groups was improved significantly, but the increment of （FEV1/FVC）% and FEVI% in the group CT was more obvious than that in the group T （P〈0.05）.The CRP levels in the two groups were decreased, but the group CT （P =0. 000 0） was decreased more significant than the group T （P =0. 026 4）. The anti- Cpn antibody IgA and IgG positive rates before and after treatment had no significant changes in the two groups （P 〉 0.05）, the anti- Cpn antibody IgM positive rate only in the group CT showed significantly change （P 〈 0. 05）. Conclusion Clarithromycin combined with tiotropium bromide for treating COPD can enhance the synergic role of two drugs with better efficacy. The CT regimen is worth to be recommended in clinic.
出处
《中国药业》
CAS
2012年第24期23-24,共2页
China Pharmaceuticals
